Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nelson L Michael

Showing results (341-350 of 372) with videos related to

Pageof 38
Sort By:
Science (New York, N.Y.)|August 6, 2016
Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeysPeter Abbink, Rafael A Larocca, Rafael A De La Barrera, et al.
The Lancet. HIV|April 20, 2019
Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trialTrevor A Crowell, Donn J Colby, Suteeraporn Pinyakorn, et al.
Plos Pathogens|August 1, 2017
Rare HIV-1 transmitted/founder lineages identified by deep viral sequencing contribute to rapid shifts in dominant quasispecies during acute and early infectionGustavo H Kijak, Eric Sanders-Buell, Agnes-Laurence Chenine, et al.
JCI Insight|January 31, 2020
HIV vaccine delayed boosting increases Env variable region 2-specific antibody effector functionsDavid Easterhoff, Justin Pollara, Kan Luo, et al.
Plos Pathogens|September 15, 2017
Correction: Rare HIV-1 transmitted/founder lineages identified by deep viral sequencing contribute to rapid shifts in dominant quasispecies during acute and early infectionGustavo H Kijak, Eric Sanders-Buell, Agnes-Laurence Chenine, et al.
Immunity|January 15, 2013
Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2Hua-Xin Liao, Mattia Bonsignori, S Munir Alam, et al.
Nature|September 11, 2012
Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2Morgane Rolland, Paul T Edlefsen, Brendan B Larsen, et al.
The New England Journal of Medicine|April 6, 2012
Immune-correlates analysis of an HIV-1 vaccine efficacy trialBarton F Haynes, Peter B Gilbert, M Juliana McElrath, et al.
Science Advances|November 23, 2022
Protection against SARS-CoV-2 Omicron BA.1 variant challenge in macaques by prime-boost vaccination with Ad26.COV2.S and SpFNJingyou Yu, Paul V Thomas, Katherine McMahan, et al.
The Lancet. HIV|March 20, 2019
Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meetingBoris Julg, Lynda Dee, Jintanat Ananworanich, et al.
Pageof 38

Showing results (341-350 of 372) with videos related to

Sort By:
Pageof 38
Science (New York, N.Y.)|August 6, 2016
Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeysPeter Abbink, Rafael A Larocca, Rafael A De La Barrera, et al.
The Lancet. HIV|April 20, 2019
Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trialTrevor A Crowell, Donn J Colby, Suteeraporn Pinyakorn, et al.
Plos Pathogens|August 1, 2017
Rare HIV-1 transmitted/founder lineages identified by deep viral sequencing contribute to rapid shifts in dominant quasispecies during acute and early infectionGustavo H Kijak, Eric Sanders-Buell, Agnes-Laurence Chenine, et al.
JCI Insight|January 31, 2020
HIV vaccine delayed boosting increases Env variable region 2-specific antibody effector functionsDavid Easterhoff, Justin Pollara, Kan Luo, et al.
Plos Pathogens|September 15, 2017
Correction: Rare HIV-1 transmitted/founder lineages identified by deep viral sequencing contribute to rapid shifts in dominant quasispecies during acute and early infectionGustavo H Kijak, Eric Sanders-Buell, Agnes-Laurence Chenine, et al.
Immunity|January 15, 2013
Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2Hua-Xin Liao, Mattia Bonsignori, S Munir Alam, et al.
Nature|September 11, 2012
Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2Morgane Rolland, Paul T Edlefsen, Brendan B Larsen, et al.
The New England Journal of Medicine|April 6, 2012
Immune-correlates analysis of an HIV-1 vaccine efficacy trialBarton F Haynes, Peter B Gilbert, M Juliana McElrath, et al.
Science Advances|November 23, 2022
Protection against SARS-CoV-2 Omicron BA.1 variant challenge in macaques by prime-boost vaccination with Ad26.COV2.S and SpFNJingyou Yu, Paul V Thomas, Katherine McMahan, et al.
The Lancet. HIV|March 20, 2019
Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meetingBoris Julg, Lynda Dee, Jintanat Ananworanich, et al.
Pageof 38